Harnessing Omics Data & Molecular Subtyping to Inform Patient Stratification in Clinical & Translational Strategies in Glioblastoma Drug Development
- Join this workshop to deepen your understanding of how omics approaches and molecular subtyping are used to stratify glioblastoma patients and define target populations for new therapies
- Examining the strategic integration of multi-omics including genomics, transcriptomics, proteomics and epigenomics for a more comprehensive and clinically actionable GBM classification system
- Identifying and validating specific molecular features as robust markers for defining GBM subtypes with prognostic and predictive value
- Leveraging molecular subtyping further down the line in development to design biomarker-driven clinical trials to enrich patient experience and improve trial efficiency
- Identifying and validating novel biomarkers with a focus on their identification in discovery
- Looking towards personalized GBM treatment where therapy selection is guided by a patient’s molecular profile